Form 4: Abbott Labs EVP Sells Shares, Covers Taxes
Insider Transaction Report
Abbott Laboratories' EVP, General Counsel, and Secretary, Elizabeth C. Cushman, reported the sale of common shares to cover tax obligations and an additional sale.
Summary
- Elizabeth C. Cushman, Executive Vice President, General Counsel, and Secretary of Abbott Laboratories (ABT), reported transactions involving common shares.
- On February 27, 2026, 1,421 common shares were disposed of at a price of $116.26 per share. This transaction (Code F) typically indicates shares withheld to cover tax liabilities related to equity awards.
- Following this disposition, Ms. Cushman beneficially owned 38,836 common shares directly.
- On March 2, 2026, an additional 263 common shares were sold at a price of $115.58 per share (Code S).
- After all reported transactions, Ms. Cushman's direct beneficial ownership stands at 38,573 common shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales, primarily for tax purposes, and do not indicate a change in the company's operational or financial health.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly routine tax-related dispositions and relatively small discretionary sales, are common occurrences and generally do not signal significant shifts in company fundamentals or broader industry trends within the healthcare sector.
Stakeholder Impact
- Shareholders: The impact on shareholders is minimal, as these are routine insider transactions and do not reflect a change in company fundamentals or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 02/27/2026 | Transaction date for the disposition of 1,421 common shares (tax withholding). |
| 03/02/2026 | Transaction date for the sale of 263 common shares. |
| 03/03/2026 | Signature date of the reporting person. |
Recommendation
holdThe filing details routine insider share dispositions, primarily for tax obligations, and a small additional sale. These transactions are not indicative of any fundamental change in Abbott Laboratories' business or outlook, thus a 'hold' recommendation remains appropriate based solely on this filing.
Keywords
Abbott Laboratories, ABT, Insider Trading, Form 4, Elizabeth C. Cushman, Share Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.